$8.76
2.67% yesterday
NYSE, May 20, 10:00 pm CET
ISIN
US68622V1061
Symbol
OGN

Organon & Co. Stock price

$8.76
-1.87 17.59% 1M
-5.97 40.53% 6M
-6.16 41.29% YTD
-13.01 59.76% 1Y
-28.88 76.73% 3Y
-24.49 73.65% 5Y
-24.49 73.65% 10Y
NYSE, Closing price Tue, May 20 2025
-0.24 2.67%
ISIN
US68622V1061
Symbol
OGN
Sector
Industry

Key metrics

Market capitalization $2.28b
Enterprise Value $10.69b
P/E (TTM) P/E ratio 3.03
EV/FCF (TTM) EV/FCF 13.75
EV/Sales (TTM) EV/Sales 1.70
P/S ratio (TTM) P/S ratio 0.36
P/B ratio (TTM) P/B ratio 4.17
Dividend yield 12.79%
Last dividend (FY24) $1.12
Revenue growth (TTM) Revenue growth -0.84%
Revenue (TTM) Revenue $6.29b
EBIT (operating result TTM) EBIT $1.41b
Free Cash Flow (TTM) Free Cash Flow $777.00m
Cash position $547.00m
EPS (TTM) EPS $2.89
P/E forward 2.31
P/S forward 0.36
EV/Sales forward 1.70
Short interest 10.08%
Show more

Is Organon & Co. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Organon & Co. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Organon & Co. forecast:

2x Buy
25%
3x Hold
38%
3x Sell
38%

Analyst Opinions

8 Analysts have issued a Organon & Co. forecast:

Buy
25%
Hold
38%
Sell
38%

Financial data from Organon & Co.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
6,294 6,294
1% 1%
100%
- Direct Costs 2,695 2,695
4% 4%
43%
3,599 3,599
4% 4%
57%
- Selling and Administrative Expenses 1,446 1,446
12% 12%
23%
- Research and Development Expense 453 453
11% 11%
7%
1,700 1,700
7% 7%
27%
- Depreciation and Amortization 295 295
21% 21%
5%
EBIT (Operating Income) EBIT 1,405 1,405
4% 4%
22%
Net Profit 750 750
28% 28%
12%

In millions USD.

Don't miss a Thing! We will send you all news about Organon & Co. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Organon & Co. Stock News

Neutral
PRNewsWire
about 19 hours ago
SAN DIEGO , May 20, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Organon & Co. (NYSE: OGN) focused on whether Organon as well as certain of its executives made false and/or misleading statements and/or failed to disclose material information to investors. If you have information that could a...
Positive
Seeking Alpha
9 days ago
Initiate Strong Buy on Organon & Co. with $26.4 PT, driven by cost savings, Nexplanon momentum, and biosimilars diversification offsetting Established Brands LOE. Forecasted EPS of $4.00 (FY25; +20.1% Y/Y) and $4.40 (FY26; +10.0%), well above consensus, supported by operational leverage and dividend cut for deleveraging. Transformational cost savings of >$200M by FY25 and $275M by FY26, driving...
Neutral
PRNewsWire
11 days ago
SAN DIEGO , May 10, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Organon & Co. (NYSE: OGN) focused on whether Organon as well as certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors. If you have information that could assist in the...
More Organon & Co. News

Company Profile

Organon & Co. is a science based global pharmaceutical company that develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020 and is headquartered in Jersey City, NJ.

Head office United States
CEO Kevin Ali
Employees 10,000
Founded 2020
Website www.organon.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today